Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Irvine UCSD
Dates
study started
completion around

Description

Summary

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

Official Title

A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer

Keywords

Carcinoma, Non-small-Cell Lung, Non-Small-Cell Lung Carcinoma, Carboplatin, Pemetrexed, Amivantamab-vmjw, Heparin, Low-Molecular-Weight Heparin, Tinzaparin, Dalteparin, Anticoagulants, Lazertinib, Amivantamab, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH), Cohort6(Exon19del/Exon21L858R,NSCLC1L,PreviouslyUntreated):Amivantamab(Q2W)+Lazertinib+Anticoagulant

Eligibility

Locations

  • University of California at San Diego accepting new patients
    La Jolla California 92093 United States
  • University of California Irvine accepting new patients
    Orange California 92868 United States
  • Stanford Cancer Institute accepting new patients
    Stanford California 94305 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Janssen Research & Development, LLC
ID
NCT05498428
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 390 study participants
Last Updated